Unusual Biotransformation of a Pyrrolotriazine Heterocycle

Sci Update

Biotransformations can be diverse and not limited to simple oxidation or dealkylation. An oncologic agent, The BMS-690514, is an example of unexpected metabolism. This compound undergoes multiple biotransformations, among them are P450 mediated oxidations of its heterocycle pyrrolotriazine group. Two major metabolites A and B are resulting from + O biotransformation.  However if the metabolite A shows a hydroxylation of the heterocycle, the metabolite B seems to undergone a unusual rearrangement. The isolation of that metabolite demonstrated the formation a hydroxypyridotriazine group.

This structure was confirmed using NMR spectrometry. The metabolism study of deuterium and tritium isotope label at the oxidized position showed that the label was retain during the formation of the metabolite A and lost during the formation of the metabolite B. The authors concluded that this metabolite was formed via epoxidation.

Haizheng Hong et al. Chem. Res. Toxicol. 201124, 125-134.

Photochemistry

Hepatochem offers a variety of photochemistry reactors and accessories that are used throughout the world to explore chemical conditions. All of our reactors are compatible with most vial formats and stirring plates. We also offer several photochemistry screening kits for calibration and accuracy.

Request Form

Interested in learning more about our products?
Complete our request form and we'll get back to you as soon as possible.

The Biomimetic Advantage

While microsomes have proven valuable as a predictive tool, their productive capabilities are limited. Biomimetic Chemistry, on the other hand, possesses the advantages of both chemistry and biology and is thus a much more efficient tool for metabolite synthesis.

See our Side By Side Comparison Chart Here

Metabolite Synthesis

Through our revolutionary technology, HepatoChem enables cost effective testable quantities of metabolites in-house even at the earliest stages of drug discovery. This new capability, which enables affordable early metabolite toxicity testing, offers drug companies the opportunity to save millions each year through dramatically improved drug pipelines.